Pyxis Oncology/$PYXS
1D1W1MYTD1Y5YMAX
Capital at risk
About Pyxis Oncology
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
- Ticker
- $PYXS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 56
- Headquarters
- Boston, United States
- Website
- www.pyxisoncology.com
Pyxis Oncology Metrics
BasicAdvanced
$324M
-
-$1.40
1.32
-
Price and volume
Market cap
$324M
Beta
1.32
52-week high
$5.55
52-week low
$1.03
Average daily volume
1.3M
Financial strength
Current ratio
1.337
Quick ratio
1.201
Long term debt to equity
139.93
Total debt to equity
155.874
Profitability
EBITDA (TTM)
-85.526
Gross margin (TTM)
78.37%
Net profit margin (TTM)
-803.83%
Operating margin (TTM)
-812.74%
Effective tax rate (TTM)
-1.26%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-62.95%
Return on equity (TTM)
-179.10%
Valuation
Price to revenue (TTM)
22.29
Price to book
21.57
Price to tangible book (TTM)
21.57
Price to free cash flow (TTM)
-3.622
Free cash flow yield (TTM)
-27.61%
Free cash flow per share (TTM)
-1.074
Growth
Revenue change (TTM)
291.42%
Earnings per share change (TTM)
-10.77%
3-year earnings per share growth (CAGR)
-20.61%
What the Analysts think about Pyxis Oncology
Analyst ratings (Buy, Hold, Sell) for Pyxis Oncology stock.
Analyst projections of the future price of Pyxis Oncology stock.
Bulls say / Bears say
In June 2026, Pyxis Oncology entered into a private placement expected to generate up to $114 million in gross proceeds, extending its cash runway into the second quarter of 2027 and supporting key MICVO clinical milestones (SEC 8-K)
At the AACR Annual Meeting 2026, preclinical data demonstrated that a mouse analogue of MICVO achieved dose-dependent tumor inhibition and synergistic activity with anti-PD-1 in a refractory HNSCC model, validating its novel extracellular matrix–targeting mechanism (Investing.com)
Pyxis Oncology maintains a strategic collaboration with Merck to evaluate MICVO in combination with KEYTRUDA® in a Phase 1/2 study for first- and second-line R/M HNSCC, potentially broadening its clinical utility and commercial appeal (SEC Form 10-Q)
In May 2026, Pyxis Oncology reported a first-quarter net loss of $23.3 million and flagged substantial doubt about its ability to continue as a going concern without additional capital (Reuters)
For the year ended December 31, 2025, R&D expenses rose 25.5% to $74 million as net loss widened to $79.6 million, significantly increasing the company’s cash burn rate (Reuters)
The June 2026 private placement includes common warrants for up to $64 million of additional proceeds, posing potential for substantial shareholder dilution if fully exercised (SEC 8-K)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Pyxis Oncology Financial Performance
Revenues and expenses
Pyxis Oncology Earnings Performance
Company profitability
Upcoming events
No upcoming events
Pyxis Oncology News
AllArticlesVideos
Funds containing Pyxis Oncology
AllUSDGBP
Fund name | Fund size | $PYXS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.